Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 368274, 15 pages
http://dx.doi.org/10.1155/2014/368274
Review Article

The Spectrum of Anti-Chromatin/Nucleosome Autoantibodies: Independent and Interdependent Biomarkers of Disease

1Department of Clinical Immunology, JIPMER, 605006 Puducherry, India
2Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AlB, Canada T2N 4N1

Received 13 January 2014; Accepted 3 March 2014; Published 3 April 2014

Academic Editor: Michael Mahler

Copyright © 2014 Sonal Mehra and Marvin J. Fritzler. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Luger, A. W. Mäder, R. K. Richmond, D. F. Sargent, and T. J. Richmond, “Crystal structure of the nucleosome core particle at 2.8 Å resolution,” Nature, vol. 389, no. 6648, pp. 251–260, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. P. R. Walker and M. Sikorska, “Chromatin structure. Further evidence against the existence of a beaded subunit for the 30-nm fiber,” Journal of Biological Chemistry, vol. 262, no. 25, pp. 12218–12222, 1987. View at Google Scholar · View at Scopus
  3. R. L. Rubin and M. J. Fritzler, “Antibodies to histones and nucleosome-related antigens,” in Dubois' Lupus Erythematosus, D. J. Wallace and B. H. Hahn, Eds., pp. 464–486, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 7 edition, 2007. View at Google Scholar
  4. R. W. Burlingame and R. Cervera, “Anti-chromatin (anti-nucleosome) autoantibodies,” Autoimmunity Reviews, vol. 1, no. 6, pp. 321–328, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. R. W. Burlingame, “Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies,” Clinical and Applied Immunology Reviews, vol. 4, no. 5, pp. 351–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Düzgün, M. Şahin, Y. Genç, and H. Tutkak, “Antinucleosome antibodies and systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1109, pp. 421–428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Půtová, C. Dostal, and R. Becvar, “Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases,” Annals of the New York Academy of Sciences, vol. 1109, pp. 275–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Bizzaro, D. Villalta, D. Giavarina, and R. Tozzoli, “Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis,” Autoimmunity Reviews, vol. 12, pp. 97–106, 2012. View at Google Scholar
  9. G. Riemekasten and B. H. Hahn, “Key autoantigens in SLE,” Rheumatology, vol. 44, no. 8, pp. 975–982, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Racanelli, M. Prete, G. Musaraj, F. Dammacco, and F. Perosa, “Autoantibodies to intracellular antigens: generation and pathogenetic role,” Autoimmunity Reviews, vol. 10, no. 8, pp. 503–508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. V. N. Buneva, M. A. Krasnorutskii, and G. A. Nevinsky, “Natural antibodies to nucleic acids,” Biochemistry, vol. 78, pp. 127–143, 2013. View at Google Scholar
  12. Y. Shoenfeld and E. Toubi, “Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential,” Arthritis and Rheumatism, vol. 52, no. 9, pp. 2599–2606, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Shapira, B.-S. P. Katz, B. Gilburd et al., “Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults,” Clinical Reviews in Allergy and Immunology, vol. 42, pp. 154–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. B. Winfield, I. Fairferman, and D. Koffler, “Avidity of anti DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus,” Journal of Clinical Investigation, vol. 59, no. 1, pp. 90–96, 1977. View at Google Scholar · View at Scopus
  15. R. J. T. Smeenk, “Detection of antibodies to dsDNA: current insights into its relevance,” Clinical and Experimental Rheumatology, vol. 20, no. 3, pp. 294–300, 2002. View at Google Scholar · View at Scopus
  16. R. J. T. Smeenk, J. H. M. Berden, and A. J. G. Swaak, “dsDNA autoantibodies,” in Autoantibodies, J. B. Peter and Y. Shoenfeld, Eds., pp. 227–236, Elsevier Science, Amsterdam, The Netherlands, 1996. View at Google Scholar
  17. M. C. Hochberg, “Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 40, no. 9, p. 1725, 1997. View at Google Scholar · View at Scopus
  18. M. Petri, A. M. Orbai, G. S. Alarcon et al., “Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 64, pp. 2677–2686, 2012. View at Google Scholar
  19. R. Gualtierotti, M. Biggioggero, A. E. Penatti, and P. L. Meroni, “Updating on the pathogenesis of systemic lupus erythematosus,” Autoimmunity Reviews, vol. 10, no. 1, pp. 3–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. M. Stinton, S. G. Barr, L. A. Tibbles et al., “Autoantibodies in lupus nephritis patients requiring renal transplantation,” Lupus, vol. 16, no. 6, pp. 394–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. López-Hoyos, R. Cabeza, V. M. Martínez-Taboada et al., “Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus,” Lupus, vol. 14, no. 7, pp. 505–509, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. S. Mortensen, K. A. Fenton, and O. P. Rekvig, “Lupus nephritis: the central role of nucleosomes revealed,” American Journal of Pathology, vol. 172, no. 2, pp. 275–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Seredkina, J. van der Vlag, J. Berden, E. Mortensen, and O. P. Rekvig , “Lupus nephritis: enigmas, conflicting models and an emerging concept,” Molecular Medicine, vol. 19, pp. 161–169, 2013. View at Google Scholar
  24. Z. Amoura, J.-C. Piette, J.-F. Bach, and S. Koutouzov, “The key role of nucleosomes in lupus,” Arthritis & Rheumatism, vol. 42, pp. 833–843, 1999. View at Google Scholar
  25. J. H. M. Berden, “Lupus nephritis,” Kidney International, vol. 52, no. 2, pp. 538–558, 1997. View at Google Scholar · View at Scopus
  26. D.-J. Min, S.-J. Kim, S.-H. Park et al., “Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody,” Clinical and Experimental Rheumatology, vol. 20, no. 1, pp. 13–18, 2002. View at Google Scholar · View at Scopus
  27. Z. Amoura, S. Koutouzov, H. Chabre et al., “Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 43, pp. 76–84, 2000. View at Google Scholar
  28. A. P. Cairns, S. A. McMillan, A. D. Crockard et al., “Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 62, no. 3, pp. 272–273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Cervera, O. Viñas, M. Ramos-Casals et al., “Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy,” Annals of the Rheumatic Diseases, vol. 62, no. 5, pp. 431–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. O. A. Gutiérrez-Adrianzén, S. Koutouzov, R. M. Salani Mota, M. M. das Chagas Medeiros, J.-F. Bach, and H. de Holanda Campos, “Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies,” Journal of Rheumatology, vol. 33, no. 8, pp. 1538–1544, 2006. View at Google Scholar · View at Scopus
  31. P. Decker, “Nucleosome autoantibodies,” Clinica Chimica Acta, vol. 366, no. 1-2, pp. 48–60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Decker, H. Singh-Jasuja, S. Haager, I. Kötter, and H.-G. Rammensee, “Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation,” Journal of Immunology, vol. 174, no. 6, pp. 3326–3334, 2005. View at Google Scholar · View at Scopus
  33. B. D. Stollar, “Antibodies to DNA,” CRC Critical Reviews in Biochemistry, vol. 20, no. 1, pp. 1–36, 1986. View at Google Scholar · View at Scopus
  34. B. D. Stollar, “The origin and pathogenic role of anti-DNA autoantibodies,” Current Opinion in Immunology, vol. 2, no. 4, pp. 607–612, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Koutouzov, A. L. Jeronimo, H. Campos, and Z. Amoura, “Nucleosomes in the pathogenesis of systemic lupus erythematosus,” Rheumatic Disease Clinics of North America, vol. 30, no. 3, pp. 529–558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. W. C. Dieker, J. van der Vlag, and J. H. M. Berden, “Triggers for anti-chromatin autoantibody production in SLE,” Lupus, vol. 11, no. 12, pp. 856–864, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. E. S. Mortensen and O. P. Rekvig, “Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 696–704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. K.-Y. Su and D. S. Pisetsky, “The role of extracellular DNA in autoimmunity in SLE,” Scandinavian Journal of Immunology, vol. 70, no. 3, pp. 175–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. D. S. Pisetsky, “The origin and properties of extracellular DNA: from PAMP to DAMP,” Clinical Immunology, vol. 144, pp. 32–40, 2012. View at Google Scholar
  40. A. J. Ullal, C. F. Reich III, M. Clowse et al., “Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus,” Journal of Autoimmunity, vol. 36, no. 3-4, pp. 173–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J. R. Dye, A. J. Ullal, and D. S. Pisetsky, “The role of microparticles in the pathogenesis of rheumatoid arthritis and SLE,” Scandinavian Journal of Immunology, vol. 78, pp. 140–148, 2013. View at Google Scholar
  42. C. C. van Bavel, J. Dieker, S. Muller et al., “Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies,” Molecular Immunology, vol. 47, no. 2-3, pp. 511–516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. C. van Bavel, J. W. Dieker, Y. Kroeze et al., “Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 201–207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Emlen, V. M. Holers, W. P. Arend, and B. Kotzin, “Regulation of nuclear antigen expression on the cell surface of human monocytes,” Journal of Immunology, vol. 148, no. 10, pp. 3042–3048, 1992. View at Google Scholar · View at Scopus
  45. R. W. Burlingame, R. L. Rubin, R. S. Balderas, and A. N. Theofilopoulos, “Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1687–1695, 1993. View at Google Scholar · View at Scopus
  46. D. Laderach, S. Koutouzov, J.-F. Bach, and A. M. Yamamoto, “Concomitant early appearance of anti-ribonucleoprotein and anti-nucleosome antibodies in lupus prone mice,” Journal of Autoimmunity, vol. 20, no. 2, pp. 161–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Mohan, S. Adams, V. Stanik, and S. K. Datta, “Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus,” Journal of Experimental Medicine, vol. 177, no. 5, pp. 1367–1381, 1993. View at Google Scholar · View at Scopus
  48. A. Lartigue, P. Courville, I. Auquit et al., “Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced marine lupus,” Journal of Immunology, vol. 177, no. 2, pp. 1349–1354, 2006. View at Google Scholar · View at Scopus
  49. A. Rosen and L. Casciola-Rosen, “Clearing the way to mechanisms of autoimmunity,” Nature Medicine, vol. 7, no. 6, pp. 664–665, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. C. F. Reich III and D. S. Pisetsky, “The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis,” Experimental Cell Research, vol. 315, no. 5, pp. 760–768, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Fritzler and E. M. Tan, “Antibodies to histones in drug-induced and idiopathic lupus erythematosus,” Journal of Clinical Investigation, vol. 62, no. 3, pp. 560–567, 1978. View at Google Scholar · View at Scopus
  52. N. F. Rothfield and B. D. Stollar, “The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus,” Journal of Clinical Investigation, vol. 46, no. 11, pp. 1785–1794, 1967. View at Google Scholar · View at Scopus
  53. J. P. Portanova, R. E. Arndt, E. M. Tan, and B. L. Kotzin, “Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions,” Journal of Immunology, vol. 138, no. 2, pp. 446–451, 1987. View at Google Scholar · View at Scopus
  54. R. W. Burlingame and R. L. Rubin, “Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin,” Journal of Clinical Investigation, vol. 88, no. 2, pp. 680–690, 1991. View at Google Scholar · View at Scopus
  55. J. van der Vlag and J. H. M. Berden, “Lupus nephritis: role of antinucleosome autoantibodies,” Seminars in Nephrology, vol. 31, no. 4, pp. 376–389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Amoura, H. Chabre, S. Koutouzov et al., “Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria,” Arthritis and Rheumatism, vol. 37, no. 11, pp. 1684–1688, 1994. View at Publisher · View at Google Scholar · View at Scopus
  57. R. W. Burlingame, M. L. Boey, G. Starkebaum, and R. L. Rubin, “The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 184–192, 1994. View at Google Scholar · View at Scopus
  58. H. Bagavant, U. S. Deshmukh, F. Gaskin, and S. M. Fu, “Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage,” Scandinavian Journal of Immunology, vol. 60, no. 1, pp. 52–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. U. Wellmann, M. Letz, M. Herrmann, S. Angermüller, J. R. Kalden, and T. H. Winkler, “The evolution of human anti-double-stranded DNA autoantibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9258–9263, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. L. E. Munoz, U. S. Gaipl, and M. Herrmann, “Predictive value of anti-dsDNA autoantibodies: importance of the assay,” Autoimmunity Reviews, vol. 7, no. 8, pp. 594–597, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Alarcon-Segovia, A. Ruiz-Arguelles, and E. Fishbein, “Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors,” Nature, vol. 271, no. 5640, pp. 67–69, 1978. View at Google Scholar · View at Scopus
  62. D. Alarcón-Segovia, A. Ruiz-Argüelles, and L. Llorente, “Broken dogma: penetration of autoantibodies into living cells,” Immunology Today, vol. 17, no. 4, pp. 163–164, 1996. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Putterman, “New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus,” Autoimmunity Reviews, vol. 3, no. 2, pp. 7–11, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. A.-M. Rouquette and C. Desgruelles, “Detection of antibodies to dsDNA: an overview of laboratory assays,” Lupus, vol. 15, no. 7, pp. 403–407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Mahler and M. J. Fritzler, “Anti-dsDNA antibody testing in the clinic: farr or ELISA? Commentay,” Nature Clinical Practice Rheumatology, vol. 3, no. 2, pp. 72–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. M. J. Fritzler, “Advances and applications of multiplexed diagnostic technologies in autoimmune diseases,” Lupus, vol. 15, no. 7, pp. 422–427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Desplat-Jego, N. Bardin, B. Larida, and M. Sanmarco, “Evaluation of the BioPlex 2200 ANA screen for the detection of antinuclear antibodies and comparison with conventional methods,” Annals of the New York Academy of Sciences, vol. 1109, pp. 245–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. P. J. Utz, “Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus,” Lupus, vol. 13, no. 5, pp. 304–311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Riboldi, M. Gerosa, G. Moroni et al., “Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?” Autoimmunity, vol. 38, no. 1, pp. 39–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Albon, C. Bunn, G. Swana, and Y. Karim, “Performance of a multiplex assay compared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis,” Journal of Immunological Methods, vol. 365, no. 1-2, pp. 126–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. J. G. Hanly, L. Su, V. Farewell, and M. J. Fritzler, “Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus,” Journal of Immunological Methods, vol. 358, no. 1-2, pp. 75–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. S. S. Copple, T. B. Martins, C. Masterson, E. Joly, and H. R. Hill, “Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera,” Annals of the New York Academy of Sciences, vol. 1109, pp. 464–472, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. B. B. Suh-Lailam, T. R. Chiaro, K. Wayne Davis, A. R. Wilson, and A. E. Tebo, “Evaluation of a high avidity anti-dsDNA igG enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 8, pp. 748–754, 2011. View at Google Scholar · View at Scopus
  74. A. Ghirardello, D. Villalta, G. Morozzi et al., “Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study,” Clinical and Experimental Rheumatology, vol. 29, no. 1, pp. 50–56, 2011. View at Google Scholar · View at Scopus
  75. A. Antico, S. Platzgummer, D. Bassetti, N. Bizzaro, R. Tozzoli, and D. Villalta, “Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test,” Lupus, vol. 19, no. 8, pp. 906–912, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. J. Fritzler, A. Wiik, E. M. Tan et al., “A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories,” Journal of Rheumatology, vol. 30, no. 11, pp. 2374–2381, 2003. View at Google Scholar · View at Scopus
  77. R. H. W. M. Derksen, E. J. E. G. Bast, T. Strooisma, and J. W. G. Jacobs, “A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum,” Annals of the Rheumatic Diseases, vol. 61, no. 12, pp. 1099–1102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Haugbro, J. C. Nossent, T. Winkler, Y. Figenschau, and O. P. Rekvig, “Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity,” Annals of the Rheumatic Diseases, vol. 63, no. 4, pp. 386–394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. P. D. Cary, C. Crane-Robinson, E. M. Bradbury, and G. H. Dixon, “Structural studies of the non-histone chromosomal proteins HMG-T and H6 from trout testis,” European Journal of Biochemistry, vol. 119, no. 3, pp. 545–551, 1981. View at Google Scholar · View at Scopus
  80. N. Bardin, S. Desplat-Jego, L. Daniel, N. Jourde Chiche, and M. Sanmarco, “BioPlexe multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus,” Autoimmunity, vol. 42, no. 1, pp. 63–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Bose, X. Wang, M. Gupta, and Q. Yao, “The clinical utility of anti-chromatin antibodies as measured by BioPlex 2200 in the diagnosis of systemic lupus erythematosus versus other rheumatic diseases,” International Journal of Clinical and Experimental Medicine, vol. 5, pp. 316–320, 2012. View at Google Scholar
  82. O. P. Rekvig, J. van der Vlag, and N. Seredkina, “Anti-nucleosome antibodies: a critical reflection on their specificities and diagnostic impact,” Arthritis & Rheumatology, 2014. View at Publisher · View at Google Scholar
  83. C. Grootscholten, J. W. C. Dieker, F. D. McGrath et al., “A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone,” Annals of the Rheumatic Diseases, vol. 66, no. 5, pp. 693–696, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Bruns, S. Bläss, G. Hausdorf, G. R. Burmester, and F. Hiepe, “Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 43, pp. 2307–2315, 2000. View at Google Scholar
  85. J. A. Simón, J. Cabiedes, E. Ortiz, J. Alcocer-Varela, and J. Sánchez-Guerrero, “Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as diagnostic tool and disease activity marker,” Rheumatology, vol. 43, no. 2, pp. 220–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Schett, J. Smolen, C. Zimmermann et al., “The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity,” Lupus, vol. 11, no. 11, pp. 704–715, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen, “Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4,” Rheumatology International, vol. 32, pp. 2445–2451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. G. A. Sardeto, L. M. Simas, T. S. Skare, R. M. Nisihara, and S. R. R. Utiyama, “Antinucleosome in systemic lupus erythematosus. A study in a Brazilian population,” Clinical Rheumatology, vol. 31, no. 3, pp. 553–556, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Suleiman, D. Kamaliah, A. Nadeem, N. N. Naing, and C. H. Che Maraina, “Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus,” International Journal of Rheumatic Diseases, vol. 12, no. 2, pp. 100–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Chabre, Z. Amoura, J.-C. Piette, P. Godeau, J.-F. Bach, and S. Koutouzov, “Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 38, no. 10, pp. 1485–1491, 1995. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Haddouk, M. B. Ayed, S. Baklouti, J. Hachicha, Z. Bahloul, and H. Masmoudi, “Clinical significance of antinucleosome antibodies in Tunisian systemic lupus erythematosus patients,” Clinical Rheumatology, vol. 24, no. 3, pp. 219–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Hmida, P. Schmit, G. Gilson, and R. L. Humbel, “Failure to detect antinucleosome antibodies in scleroderma: comment on the article by Amoura et al,” Arthritis & Rheumatology, vol. 46, pp. 280–282, 2002. View at Google Scholar
  93. A. Ghirardello, A. Doria, S. Zampieri et al., “Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients,” Journal of Autoimmunity, vol. 22, no. 3, pp. 235–240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Braun, J. Sis, R. Max et al., “Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases,” Scandinavian Journal of Rheumatology, vol. 36, no. 4, pp. 291–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. H.-A. Kim, J.-Y. Jeon, G.-S. Choi et al., “The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans,” Clinical Immunology, vol. 128, no. 2, pp. 277–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Su, R.-L. Jia, L. Han, and Z.-G. Li, “Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus,” Clinical Immunology, vol. 122, no. 1, pp. 115–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Tikly, T. Gould, A. A. Wadee, E. Westhuizen, and B. B. N. Mokgethwa, “Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus,” Clinical Rheumatology, vol. 26, no. 12, pp. 2121–2125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. P. Ghillani-Dalbin, Z. Amoura, P. Cacoub et al., “Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients,” Lupus, vol. 12, no. 11, pp. 833–837, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Witte, “IgM antibodies against dsDNA in SLE,” Clinical Reviews in Allergy and Immunology, vol. 34, no. 3, pp. 345–347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Villalta, N. Bizzaro, N. Bassi et al., “Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease,” PLoS ONE, vol. 8, Article ID e71458, 2013. View at Google Scholar
  101. A. Souza, L. M. da Silva, F. R. Oliveira, A. M. F. Roselino, and P. Louzada-Junior, “Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease,” Lupus, vol. 18, no. 3, pp. 223–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. L. Andreoli, F. Pregnolato, R. W. Burlingame et al., “Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?” Journal of Autoimmunity, vol. 30, no. 1-2, pp. 51–57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. X. Bossuyt, J. Frans, A. Hendrickx et al., “Detection of anti-nucleosome antibodies in a routine clinical laboratory setting,” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 387–388, 2008. View at Google Scholar · View at Scopus
  104. Z. Amoura, J.-C. Piette, H. Chabre et al., “Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 40, no. 12, pp. 2217–2225, 1997. View at Publisher · View at Google Scholar · View at Scopus
  105. J. A. Chen, S. Meister, V. Urbonaviciute et al., “Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus,” Autoimmunity, vol. 40, no. 4, pp. 307–310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. A. McCoubrey-Hoyer, T. B. Okarma, and H. R. Holman, “Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus,” American Journal of Medicine, vol. 77, no. 1, pp. 23–34, 1984. View at Google Scholar · View at Scopus
  107. M. H. Jørgensen, O. P. Rekvig, R. S. Jacobsen, S. Jacobsen, and K. A. Fenton, “Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus,” Immunology Letters, vol. 138, no. 2, pp. 179–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Williams R.C., C. C. Malone, C. Meyers, P. Decker, and S. Muller, “Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7,” Journal of Rheumatology, vol. 28, no. 1, pp. 81–94, 2001. View at Google Scholar · View at Scopus
  109. S. P. Keusseyan, N. P. Silva, M. O. Hilario, E. M. Okuda, M. T. Terreri, and L. E. Andrade, “Diagnostic performance and clinical associations of antibodies to the chromatin antigenic system in juvenile systemic lupus erythematosus,” Revista Brasileira de Reumatologia, vol. 52, pp. 703–712, 2012. View at Google Scholar
  110. L. M. Campos, M. H. Kiss, M. A. Scheinberg, C. L. Mangueira, and C. A. Silva, “Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus,” Lupus, vol. 15, pp. 496–500, 2006. View at Google Scholar
  111. A. A. Jesus, L. M. Campos, B. L. Liphaus et al., “Anti-C1q, anti-chromatin/nucleosome, and anti-dsDNA antibodies in juvenile systemic lupus erythematosus patients,” Revista Brasileira de Reumatologia, vol. 52, pp. 976–981, 2012. View at Google Scholar
  112. J.-F. Wu, Y.-H. Yang, L.-C. Wang, J.-H. Lee, E.-Y. Shen, and B.-L. Chiang, “Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus,” Journal of Autoimmunity, vol. 27, no. 2, pp. 119–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. L. Zhang, A. M. Bertucci, R. Ramsey-Goldman, E. R. Harsha-Strong, R. K. Burt, and S. K. Datta, “Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity,” Clinical Immunology, vol. 149, pp. 365–378, 2013. View at Google Scholar
  114. E. W. Johns, “History, definitions, and problems,” in The HMG Cromosomal Proteins, E. W. Johns, Ed., pp. 1–8, Academic Press, New York, NY, USA, 1982. View at Google Scholar
  115. J. S. Zlatanova, “Immunochemical approaches to the study of histone H1 and high mobility group chromatin proteins,” Molecular and Cellular Biochemistry, vol. 92, no. 1, pp. 1–22, 1990. View at Google Scholar · View at Scopus
  116. National Library of Medicine, “High Mobility Group Proteins,” 2014, http://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?mode=&term=High+Mobility+Group+Proteins.
  117. S. Weisbrod and H. Weintraub, “Isolation of a subclass of nuclear proteins responsible for conferring a DNase I-sensitive structure on globin chromatin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 2, pp. 630–634, 1979. View at Google Scholar · View at Scopus
  118. P. J. Gonzalez and E. Palacian, “Structural and transcriptional properties of different nucleosomal particles containing high mobility group proteins 14 and 17 (HMG 14/17),” Journal of Biological Chemistry, vol. 265, no. 14, pp. 8225–8229, 1990. View at Google Scholar · View at Scopus
  119. J. K. W. Mardian, A. E. Paton, G. J. Bunick, and D. E. Olins, “Nucleosome cores have two specific binding sites for nonhistone chromosomal proteins HMG 14 and HMG 17,” Science, vol. 209, no. 4464, pp. 1534–1536, 1980. View at Google Scholar · View at Scopus
  120. G. Sandeen, W. I. Wood, and G. Felsenfeld, “The interaction of high mobility proteins HMG14 and 17 with nucleosomes,” Nucleic Acids Research, vol. 8, no. 17, pp. 3757–3778, 1980. View at Publisher · View at Google Scholar · View at Scopus
  121. M. Bustin, P. S. Becerra, M. P. Crippa, D. A. Lehn, J. M. Pash, and J. Shiloach, “Recombinant human chromosomal proteins HMG-14 and HMG-17,” Nucleic Acids Research, vol. 19, no. 11, pp. 3115–3121, 1991. View at Google Scholar · View at Scopus
  122. M. Bustin, J. Reisch, L. Einck, and J. H. Klippel, “Autoantibodies to nucleosomal proteins: antibodies to HMG-17 in autoimmune diseases,” Science, vol. 215, no. 4537, pp. 1245–1247, 1982. View at Google Scholar · View at Scopus
  123. A. Hayashi, H. Nagafuchi, I. Ito, K. Hirota, M. Yoshida, and S. Ozaki, “Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity,” Modern Rheumatology, vol. 19, no. 3, pp. 283–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. V. Urbonaviciute, B. G. Fürnrohr, S. Meister et al., “Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE,” Journal of Experimental Medicine, vol. 205, no. 13, pp. 3007–3018, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. B. Wittemann, G. Neuer, H. Michels, H. Truckenbrodt, and F. A. Bautz, “Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 33, no. 9, pp. 1378–1383, 1990. View at Google Scholar · View at Scopus
  126. G. Neuer, M. Bustin, H. Michels, H. Truckenbrodt, and F. A. Bautz, “Autoantibodies to the chromosomal protein HMG-17 in juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 35, no. 4, pp. 472–475, 1992. View at Publisher · View at Google Scholar · View at Scopus
  127. R. W. Burlingame, R. L. Rubin, and A. M. Rosenberg, “Autoantibodies to chromatin components in juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 36, no. 6, pp. 836–841, 1993. View at Google Scholar · View at Scopus
  128. A. M. Rosenberg and D. M. Cordeiro, “Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis,” Journal of Rheumatology, vol. 27, no. 10, pp. 2489–2493, 2000. View at Google Scholar · View at Scopus
  129. J. C. Monier, J. Ritter, C. Caux et al., “Canine systemic lupus erythematosus. II: antinuclear antibodies,” Lupus, vol. 1, no. 5, pp. 287–293, 1992. View at Google Scholar · View at Scopus
  130. L. M. Ayer, R. L. Rubin, G. H. Dixon, and M. J. Fritzler, “Antibodies to HMG proteins in patients with drug-induced autoimmunity,” Arthritis and Rheumatism, vol. 37, no. 1, pp. 98–103, 1994. View at Google Scholar · View at Scopus
  131. L. M. Ayer, J.-L. Senécal, L. Martin, G. H. Dixon, and M. J. Fritzler, “Antibodies to high mobility group proteins in systemic sclerosis,” Journal of Rheumatology, vol. 21, no. 11, pp. 2071–2075, 1994. View at Google Scholar · View at Scopus
  132. H. Uesugi, S. Ozaki, J. Sobajima et al., “Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases,” Journal of Rheumatology, vol. 25, no. 4, pp. 703–709, 1998. View at Google Scholar · View at Scopus
  133. J. H. Morse, R. J. Barst, M. Fotino, Y. Zhang, E. Flaster, and M. J. Fritzler, “Primary pulmonary hypertension: immunogenetic response to high-mobility group (HMG) proteins and histone,” Clinical and Experimental Immunology, vol. 106, no. 2, pp. 389–395, 1996. View at Google Scholar · View at Scopus
  134. J. Sobajima, S. Ozaki, F. Osakada et al., “Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2,” Clinical and Experimental Immunology, vol. 107, no. 1, pp. 135–140, 1997. View at Google Scholar · View at Scopus
  135. J. Sobajima, S. Ozaki, H. Uesugi et al., “Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC),” Clinical and Experimental Immunology, vol. 111, no. 2, pp. 402–407, 1998. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Bustin, B. Dunn, R. Gillette, E. Mendelsohn, and N. Soares, “Antigenic determinants of high mobility group chromosomal proteins 1 and 2,” Biochemistry, vol. 21, no. 26, pp. 6773–6777, 1982. View at Google Scholar · View at Scopus
  137. S. Fida, M. A. Myers, S. Whittingham, M. J. Rowley, S. Ozaki, and I. R. Mackay, “Autoantibodies to the transcriptional factor SOX13 in primary biliary cirrhosis compared with other diseases,” Journal of Autoimmunity, vol. 19, no. 4, pp. 251–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. H. Kasimiotis, M. A. Myers, A. Argentaro et al., “Sex-determining region Y-related protein SOX13 is a diabetes autoantigen expressed in pancreatic islets,” Diabetes, vol. 49, no. 4, pp. 555–561, 2000. View at Google Scholar · View at Scopus
  139. R. Manthorpe, H. Permin, and U. Tage-Jensen, “Auto-antibodies in Sjogren's syndrome. With special reference to liver-cell membrane antibody (LMA),” Scandinavian Journal of Rheumatology, vol. 8, no. 3, pp. 168–172, 1979. View at Google Scholar · View at Scopus
  140. S. Barnay-Verdier, L. Fattoum, C. Borde, S. Kaveri, S. Gibot, and V. Maréchal, “Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock,” Intensive Care Medicine, vol. 37, no. 6, pp. 957–962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. T. Nakano, C.-Y. Lai, S. Goto et al., “Role of antinuclear antibodies in experimental and clinical liver transplantation,” Transplantation Proceedings, vol. 38, no. 10, pp. 3605–3606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. T. Nakano, S. Goto, C.-Y. Lai et al., “Experimental and clinical significance of antinuclear antibodies in liver transplantation,” Transplantation, vol. 83, no. 8, pp. 1122–1125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. M. E. Bianchi, L. Falciola, S. Ferrari, and D. M. J. Lilley, “The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins,” The EMBO Journal, vol. 11, no. 3, pp. 1055–1063, 1992. View at Google Scholar · View at Scopus
  144. M. E. Bianchi and A. Manfredi, “Chromatin and cell death,” Biochimica et Biophysica Acta—Gene Structure and Expression, vol. 1677, no. 1–3, pp. 181–186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  145. H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999. View at Publisher · View at Google Scholar · View at Scopus
  146. P. Scaffidi, T. Misteli, and M. E. Bianchi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature, vol. 418, pp. 191–195, 2002. View at Google Scholar
  147. P. Rovere-Querini, A. Capobianco, P. Scaffidi et al., “HMGB1 is an endogenous immune adjuvant released by necrotic cells,” EMBO Reports, vol. 5, no. 8, pp. 825–830, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. T. Nakano, C. L. Chen, and S. Goto, “Nuclear antigens and auto/alloantibody responses: friend or foe in transplant immunology,” Clinical and Developmental Immunology, vol. 2013, Article ID 267156, 9 pages, 2013. View at Publisher · View at Google Scholar
  150. E. Abraham, J. Arcaroli, A. Carmody, H. Wang, and K. J. Tracey, “Cutting edge: HMG-1 as a mediator of acute lung inflammation,” Journal of Immunology, vol. 165, no. 6, pp. 2950–2954, 2000. View at Google Scholar · View at Scopus
  151. B. Degryse, T. Bonaldi, P. Scaffidi et al., “The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells,” Journal of Cell Biology, vol. 152, no. 6, pp. 1197–1206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Tsung, R. Sahai, H. Tanaka et al., “The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion,” Journal of Experimental Medicine, vol. 201, no. 7, pp. 1135–1143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  153. H. Sawa, T. Ueda, Y. Takeyama et al., “Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis,” World Journal of Gastroenterology, vol. 12, no. 47, pp. 7666–7670, 2006. View at Google Scholar · View at Scopus
  154. R. S. Goldstein, A. Bruchfeld, L. Yang et al., “Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis,” Molecular Medicine, vol. 13, no. 3-4, pp. 210–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. N. Hamada, T. Maeyama, T. Kawaguchi et al., “The role of high mobility group box1 in pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 4, pp. 440–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. S. Muhammad, W. Barakat, S. Stoyanov et al., “The HMGB1 receptor RAGE mediates ischemic brain damage,” Journal of Neuroscience, vol. 28, no. 46, pp. 12023–12031, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. T. Hoshina, K. Kusuhara, K. Ikeda, Y. Mizuno, M. Saito, and T. Hara, “High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease,” Scandinavian Journal of Rheumatology, vol. 37, no. 6, pp. 445–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. D. J. Kaczorowski, A. Nakao, R. Vallabhaneni et al., “Mechanisms of toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart,” Transplantation, vol. 87, no. 10, pp. 1455–1463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. Y. Albayrak, A. Albayrak, M. Celik et al., “High mobility group box protein-1 (HMGB-1) as a new diagnostic marker in patients with acute appendicitis,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, vol. 19, article 27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. T. Kohno, T. Anzai, H. Shimizu et al., “Impact of serum high-mobility group box 1 protein elevation on oxygenation impairment after thoracic aortic aneurysm repair,” Heart and Vessels, vol. 26, no. 3, pp. 306–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. R. Takahata, S. Ono, H. Tsujimoto et al., “Postoperative serum concentrations of high mobility group box chromosomal protein-1 correlates to the duration of SIRS and pulmonary dysfunction following gastrointestinal surgery,” Journal of Surgical Research, vol. 170, no. 1, pp. e135–e140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  162. J. Choi, H. J. Min, and J.-S. Shin, “Increased levels of HMGB1 and pro-inflammatory cytokines in children with febrile seizures,” Journal of Neuroinflammation, vol. 8, article 135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. R. Haraba, V. I. Suica, E. Uyy, L. Ivan, and F. Antohe, “Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein,” Cell and Tissue Research, vol. 346, no. 3, pp. 361–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. K. Naruse, T. Sado, T. Noguchi et al., “Peripheral RAGE (Receptor for Advanced Glycation Endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response,” Journal of Reproductive Immunology, vol. 93, no. 2, pp. 69–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  165. A. Albayrak, M. H. Uyanik, S. Cerrah et al., “Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment?” Viral Immunology, vol. 23, no. 6, pp. 633–638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. R. R. Zhou, H. B. Liu, J. P. Peng et al., “High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury,” Experimental and Molecular Pathology, vol. 93, pp. 213–219, 2012. View at Google Scholar
  167. R.-R. Zhou, S.-S. Zhao, M.-X. Zou et al., “HMGB1 cytoplasmic translocation in patients with acute liver failure,” BMC Gastroenterology, vol. 11, article 21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. R. E. Voll, V. Urbonaviciute, B. Fürnrohr, M. Herrmann, and J. R. Kalden, “The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases,” Current Rheumatology Reports, vol. 10, no. 5, pp. 341–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  169. D. S. Pisetsky, H. Erlandsson-Harris, and U. Andersson, “High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease,” Arthritis Research and Therapy, vol. 10, no. 3, article 209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  170. Z. Wen, L. Xu, X. Chen et al., “Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway,” The Journal of Immunology, vol. 190, pp. 5411–5422, 2013. View at Google Scholar
  171. D. A. Abdulahad, J. Westra, J. Bijzet et al., “Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations,” Arthritis Research& Therapy, vol. 14, p. R184, 2012. View at Google Scholar
  172. P. Santoro, M. de Andrea, G. Migliaretti, C. Trapani, S. Landolfo, and M. Gariglio, “High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases,” Journal of Rheumatology, vol. 29, no. 1, pp. 90–93, 2002. View at Google Scholar · View at Scopus
  173. J. Li, H. Xie, T. Wen, H. Liu, W. Zhu, and X. Chen, “Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus,” Journal of Rheumatology, vol. 37, no. 4, pp. 766–775, 2010. View at Publisher · View at Google Scholar · View at Scopus
  174. J. Cardinal, P. Pan, R. Dhupar et al., “Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury,” Hepatology, vol. 50, no. 2, pp. 565–574, 2009. View at Publisher · View at Google Scholar · View at Scopus
  175. T. Kohno, T. Anzai, H. Kaneko et al., “High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm,” Journal of Cardiology, vol. 59, no. 3, pp. 299–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  176. V. Urbonaviciute and R. E. Voll, “High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus,” Journal of Internal Medicine, vol. 270, no. 4, pp. 309–318, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. C. Ye, J. G. Choi, S. Abraham et al., “Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, pp. 21052–21057, 2012. View at Google Scholar
  178. R. Haraba, E. Uyy, V. I. Suica, L. Ivan, and F. Antohe, “Fluvastatin reduces the high mobility group box 1 protein expression in hyperlipidemia,” International Journal of Cardiology, vol. 150, no. 1, pp. 105–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. V. Brinkmann, U. Reichard, C. Goosmann et al., “Neutrophil extracellular traps kill bacteria,” Science, vol. 303, no. 5663, pp. 1532–1535, 2004. View at Publisher · View at Google Scholar · View at Scopus
  180. V. Brinkmann and A. Zychlinsky, “Neutrophil extracellular traps: is immunity the second function of chromatin?” The Journal of Cell Biology, vol. 198, pp. 773–783, 2012. View at Google Scholar
  181. B. G. Yipp and P. Kubes, “NETosis: how vital is it?” Blood, vol. 122, pp. 2784–2794, 2013. View at Google Scholar
  182. K. Pittman and P. Kubes, “Damage-associated molecular patterns control neutrophil recruitment,” Journal of Innate Immunity, vol. 5, pp. 315–323, 2013. View at Google Scholar
  183. V. Papayannopoulos, K. D. Metzler, A. Hakkim, and A. Zychlinsky, “Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps,” Journal of Cell Biology, vol. 191, no. 3, pp. 677–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. A. Hakkim, B. G. Fürnrohr, K. Amann et al., “Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 21, pp. 9813–9818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  185. T. A. Fuchs, U. Abed, C. Goosmann et al., “Novel cell death program leads to neutrophil extracellular traps,” Journal of Cell Biology, vol. 176, no. 2, pp. 231–241, 2007. View at Publisher · View at Google Scholar · View at Scopus
  186. B. McDonald, R. Urrutia, B. G. Yipp, C. N. Jenne, and P. Kubes, “Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis,” Cell Host & Microbe, vol. 12, pp. 324–333, 2012. View at Google Scholar
  187. D. Simon, H. U. Simon, and S. Yousefi, “Extracellular DNA traps in allergic, infectious, and autoimmune diseases,” Allergy, vol. 68, pp. 409–416, 2013. View at Google Scholar
  188. T. Dörner, “SLE in 2011: deciphering the role of NETs and networks in SLE,” Nature Reviews Rheumatology, vol. 8, no. 2, pp. 68–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  189. J. E. Craft, “Dissecting the immune cell mayhem that drives lupus pathogenesis,” Science Translational Medicine, vol. 3, no. 73, Article ID 73ps9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  190. R. Lande, D. Ganguly, V. Facchinetti et al., “Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus,” Science Translational Medicine, vol. 3, no. 73, Article ID 73ra19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. G. S. Garcia-Romo, S. Caielli, B. Vega et al., “Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus,” Science Translational Medicine, vol. 3, no. 73, Article ID 73ra20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  192. E. Villanueva, S. Yalavarthi, C. C. Berthier et al., “Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus,” Journal of Immunology, vol. 187, no. 1, pp. 538–552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. J. Leffler, M. Martin, B. Gullstrand et al., “Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease,” Journal of Immunology, vol. 188, no. 7, pp. 3522–3531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  194. C. N. Jenne and P. Kubes, “NETs tangle with HIV,” Cell Host & Microbe, vol. 12, pp. 5–7, 2012. View at Google Scholar
  195. C. N. Jenne, C. H. Wong, F. J. Zemp et al., “Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps,” Cell Host & Microbe, vol. 13, pp. 169–180, 2013. View at Google Scholar
  196. K. Kessenbrock, M. Krumbholz, U. Schönermarck et al., “Netting neutrophils in autoimmune small-vessel vasculitis,” Nature Medicine, vol. 15, no. 6, pp. 623–625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  197. M. Phillipson and P. Kubes, “The neutrophil in vascular inflammation,” Nature Medicine, vol. 17, no. 11, pp. 1381–1390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  198. P. Kubes and W. Z. Mehal, “Sterile inflammation in the liver,” Gastroenterology, vol. 143, pp. 1158–1172, 2012. View at Google Scholar